Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 7/20 | 0.66 |
| ▸ | CCR1 | P32246 | 5/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2213158 | 0.91 | CCR3 (0.55) | CCR3CCR1SIGMAR1MCHR1MEN1 | |
| SCHEMBL2213271 | 0.90 | CCR3 (0.64) | CCR3CCR1SIGMAR1MCHR1MEN1 | |
| SCHEMBL16434219 | 0.90 | CCR3 (0.61) | CCR3CCR1SIGMAR1MCHR1MEN1 | |
| SCHEMBL2210703 | 0.90 | CCR3 (0.61) | CCR3CCR1SIGMAR1MCHR1MEN1 | |
| SCHEMBL2210705 | 0.89 | CCR3 (0.60) | CCR3CCR1SIGMAR1MCHR1MEN1 | |
| SCHEMBL2213561 | 0.89 | CCR3 (0.67) | CCR3CCR1SIGMAR1MCHR1MEN1 | |
| SCHEMBL2210858 | 0.86 | CCR3 (0.64) | CCR3CCR1SIGMAR1MCHR1MEN1 | |
| SCHEMBL2214002 | 0.85 | CCR3 (0.62) | CCR3CCR1SIGMAR1MCHR1MEN1 | |
| SCHEMBL2213655 | 0.84 | CCR3 (0.64) | CCR3CCR1SIGMAR1MCHR1MEN1 | |
| SCHEMBL2212518 | 0.83 | CCR3 (0.70) | CCR3CCR1SIGMAR1MCHR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1389616-B1 | 3,4-Dihalobenzylpiperidine derivatives and their medical use | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-7115635-B2 | Benzylpiperidine compound | MITSUBISHI PHARMA CORPORATION (JP) | 2006-10-03 | — | — | US | disclosed |
| US-20040158071-A1 | Chemokine inhibitors and stability in blood | MITSUBISHI PHARMA CORPORATION (JP) | 2004-08-12 | — | — | US | disclosed |
| EP-1389616-A1 | NOVEL BENZYLPIPERIDINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2004-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040158071-A1 | Chemokine inhibitors and stability in blood | CCL2, CXCR1, CCR5 | CCR3 21/4885CCR1 11/4885SIGMAR1 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.